Stop Superbugs Act

The Stop Superbugs Act would direct the National Institutes of Health's infectious disease institute to award a competitive grant to the Antibiotic Resistance Leadership Group, an existing clinical research network focused on drug-resistant infections. The grant would fund four specific activities: speeding up recruitment of participants for clinical trials, conducting outreach to recruit trial participants in community settings, coordinating the pairing of new diagnostic tools with new drug treatments during trials, and developing better methods for capturing patient-reported outcomes in research studies. The bill authorizes "such sums as may be necessary" rather than a fixed dollar amount, leaving the actual funding level to future appropriations decisions.

The bill primarily affects the research infrastructure around antibiotic-resistant infections ("superbugs") — researchers, clinical trial sites, and communities that participate in trials would be the direct beneficiaries, with potential downstream effects on the pace of development of new antibiotics and diagnostics.

The bill was introduced in the Senate on August 4, 2026, by Senator Maggie Hassan (D-NH) with Senator Roger Marshall as a cosponsor. It has been read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions, where it would need to be considered and voted on before it could advance to the full Senate. It has not yet received a committee vote or floor action.

Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.